591 results on '"Scheltens, Philip"'
Search Results
2. Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood
3. Overlap of Neuroanatomical Involvement in Frontotemporal Dementia and Primary Psychiatric Disorders: A Meta-analysis
4. Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment
5. Generating diagnostic profiles of cognitive decline and dementia using magnetoencephalography
6. Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI
7. Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study
8. Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia
9. BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project
10. Frontotemporal dementia, music perception and social cognition share neurobiological circuits: A meta-analysis
11. Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study
12. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
13. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease
14. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective
15. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project
16. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions
17. Clinician-patient communication during the diagnostic workup: The ABIDE project
18. Added value of amyloid PET in individualized risk predictions for MCI patients
19. Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease
20. Cerebrospinal fluid collection: An informative animation video for patients and caregivers
21. Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?
22. Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
23. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
24. Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project
25. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study
26. High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline
27. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly
28. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project
29. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
30. Inflammatory biomarkers in Alzheimer's disease plasma
31. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
32. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
33. Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study
34. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
35. Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease–specific regions
36. Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia
37. AMYPAD Diagnostic and Patient Management Study: Rationale and design
38. Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
39. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology
40. EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies
41. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
42. White matter hyperintensities and vascular risk factors in monozygotic twins
43. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies
44. Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders
45. Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease
46. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
47. Gray matter network measures are associated with cognitive decline in mild cognitive impairment
48. Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease
49. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory
50. Computer-assisted prediction of clinical progression in the earliest stages of AD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.